| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q04DX002 (ip) | median survival time | saline | 1.3 mg/kg/injection | 169.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 1.94 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 2.16 mg/kg/injection | 174.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 3.24 mg/kg/injection | 235.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 3.6 mg/kg/injection | 216.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 5.4 mg/kg/injection | 387.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 6.0 mg/kg/injection | 272.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 9.0 mg/kg/injection | 387.0 | Antitumor endpoint evaluated on day 45; 07/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 10.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |
| Q04DX002 (ip) | median survival time | saline | 15.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 45; 08/08 animals surviving on day 5 |